Last updated: November 2, 2026
FIBRYGA is Octapharma’s human fibrinogen concentrate for congenital fibrinogen deficiency and acquired fibrinogen deficiency in selected surgical and bleeding settings. Its market is specialized, hospital-driven, and supply constrained rather than volume driven. Product-level revenue is not publicly disclosed by Octapharma, which is privately held. Financial performance therefore must be assessed through regulatory reach, treatment adoption, plasma supply, competitor positioning, and market access rather than reported FIBRYGA sales.
FIBRYGA has FDA approval for adults and adolescents with congenital afibrinogenemia and hypofibrinogenemia, including perioperative management. In the European Union, the product is marketed for congenital fibrinogen deficiency and acquired hypofibrinogenemia under national and European regulatory frameworks. The principal commercial competitors are CSL Behring’s RiaSTAP and fibrinogen products marketed by companies including LFB and Takeda in selected geographies. [1][2][3]
What is FIBRYGA and which patients does it treat?
FIBRYGA is a lyophilized, human plasma-derived fibrinogen concentrate. Fibrinogen is converted to fibrin during coagulation and is required for stable clot formation. FIBRYGA replenishes fibrinogen when endogenous levels are absent or inadequate.
FIBRYGA approved indications
| Market |
Principal indication |
Patient population |
| United States |
Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency |
Adults and adolescents |
| United States |
Perioperative management of bleeding in congenital fibrinogen deficiency |
Adults and adolescents |
| Europe and other markets |
Congenital fibrinogen deficiency |
Country-specific labeling |
| Selected markets |
Acquired hypofibrinogenemia and related bleeding settings |
Depends on local authorization |
The U.S. label covers congenital afibrinogenemia and hypofibrinogenemia. The approved U.S. formulation is supplied as a powder for reconstitution and intravenous administration. The recommended dose depends on baseline fibrinogen concentration, body weight, and clinical bleeding status. [1]
FIBRYGA is not a mass-market chronic therapy. Treatment is episodic or perioperative, and demand is concentrated among specialized hematology, trauma, surgery, and intensive-care centers.
How large is the fibrinogen concentrate market?
The addressable market is limited by disease prevalence but supported by the clinical severity of fibrinogen deficiency and the need for rapid, standardized replacement therapy.
Congenital fibrinogen disorders are rare inherited conditions. Afibrinogenemia has been estimated at approximately one case per million people, although prevalence varies by geography and diagnosis rates. Hypofibrinogenemia and dysfibrinogenemia are more heterogeneous and may be underdiagnosed. [4]
The broader fibrinogen replacement market includes:
- Congenital afibrinogenemia and hypofibrinogenemia.
- Acquired hypofibrinogenemia during major surgery.
- Obstetric hemorrhage.
- Trauma-related bleeding.
- Cardiovascular surgery.
- Liver transplantation.
- Disseminated intravascular coagulation.
- Bleeding associated with critical illness.
The commercial opportunity is materially larger when acquired bleeding is included, but regulatory labels differ by country. FIBRYGA’s revenue exposure therefore depends on whether hospitals use it only within the congenital-deficiency label or also through local protocols and off-label practice.
Market demand drivers
Demand is supported by five factors:
- Increased recognition of fibrinogen deficiency as an actionable cause of bleeding.
- Hospital preference for standardized fibrinogen concentrates over cryoprecipitate in selected settings.
- Greater use of point-of-care coagulation testing, including viscoelastic assays.
- Expansion of specialist treatment centers for rare bleeding disorders.
- Continued need for plasma-derived therapies during major bleeding events.
Demand is constrained by the availability of cryoprecipitate, national reimbursement policies, hospital formularies, and the higher acquisition cost of concentrates in some jurisdictions.
How does FIBRYGA compare with RiaSTAP and cryoprecipitate?
FIBRYGA competes primarily with RiaSTAP, other human fibrinogen concentrates, and cryoprecipitate. The commercial choice is usually made by hospital protocols, supply availability, clinical familiarity, and reimbursement.
| Attribute |
FIBRYGA |
RiaSTAP |
Cryoprecipitate |
| Product type |
Human fibrinogen concentrate |
Human fibrinogen concentrate |
Blood component |
| Principal supplier |
Octapharma |
CSL Behring |
Blood centers and hospitals |
| Administration |
Intravenous after reconstitution |
Intravenous after reconstitution |
Transfusion |
| Dose standardization |
High |
High |
Variable |
| Pathogen-reduction profile |
Plasma-derived manufacturing controls |
Plasma-derived manufacturing controls |
Depends on collection and processing system |
| Storage and logistics |
Room-temperature storage before reconstitution, subject to label |
Product-specific storage |
Frozen storage and thawing required |
| Typical use |
Congenital deficiency and selected acquired deficiency settings |
Congenital fibrinogen deficiency |
Broad transfusion use |
| Competitive advantage |
Specialized fibrinogen replacement and global Octapharma infrastructure |
Established U.S. brand and CSL commercial reach |
Lower-cost or locally available blood product |
FIBRYGA’s principal differentiation is not a novel molecular mechanism. Its position depends on reliable supply, regulatory approvals, physician confidence, dosing performance, and access to plasma-derived manufacturing capacity.
Cryoprecipitate remains a significant substitute in the United States and other markets. It contains fibrinogen along with factor VIII, von Willebrand factor, factor XIII, and fibronectin. Concentrates provide more predictable fibrinogen dosing and reduce exposure to unnecessary plasma proteins, but their economic advantage varies by institution.
What is the FDA regulatory status of FIBRYGA?
FIBRYGA received FDA approval in 2017 for congenital fibrinogen deficiency. The product is regulated as a biologic derived from human plasma. The FDA label identifies Octapharma Pharmazeutika Produktionsgesellschaft m.b.H. as the manufacturer, with Octapharma USA responsible for U.S. commercialization. [1]
FIBRYGA U.S. regulatory milestones
| Milestone |
Date |
| FDA approval |
2017 |
| U.S. commercial availability |
2017 onward |
| Product category |
Plasma-derived biologic |
| Administration |
Intravenous |
| FDA reference source |
FIBRYGA prescribing information |
The product does not have the commercial profile of a conventional small-molecule drug. FDA exclusivity is less important than biologic manufacturing complexity, plasma sourcing, production validation, and the limited number of qualified suppliers.
What is the Orange Book and Purple Book status of FIBRYGA?
FIBRYGA is a biologic, so its principal regulatory reference is the FDA Purple Book rather than the Orange Book. The Orange Book is used primarily for approved small-molecule drug products and associated patent certifications. [5]
Orange Book status
FIBRYGA does not have the standard Orange Book framework associated with an ANDA generic. A conventional Paragraph IV challenge is therefore not the normal pathway for competing FIBRYGA products.
Purple Book and biosimilar status
A competing product would generally need to proceed through the biologics license application framework, potentially including a biosimilar pathway if the reference-product and product-class requirements are satisfied. The commercial risk from biosimilars is lower than for major monoclonal antibodies because the fibrinogen market is small, plasma-derived, and manufacturing intensive.
A biosimilar or interchangeable designation would not automatically provide rapid market access. A competing manufacturer would still need:
- A qualified plasma supply network.
- Validated fractionation and purification processes.
- Demonstrated consistency and product quality.
- Regulatory approval in each target market.
- Hospital and specialist adoption.
- Sufficient manufacturing scale to support emergency demand.
The FDA Purple Book should be checked for current reference-product and biosimilar listings. [5]
What patents protect FIBRYGA?
FIBRYGA’s commercial protection is primarily manufacturing-based rather than dependent on a conventional composition-of-matter patent.
Potentially relevant intellectual-property categories include:
- Plasma collection and screening.
- Fractionation and purification of fibrinogen.
- Viral inactivation and clearance.
- Stabilization and lyophilization.
- Formulation and reconstitution.
- Container-closure systems.
- Manufacturing controls and analytical methods.
- Process know-how and trade secrets.
The public commercial record does not establish a single, dominant FIBRYGA patent that determines market entry in the manner of a branded small molecule. The absence of a conventional Orange Book patent listing reduces the relevance of standard Paragraph IV litigation analysis.
How strong is the FIBRYGA patent estate?
The estate is best characterized as process- and know-how-dependent. That structure can be commercially durable because a rival cannot simply copy the product formulation and launch. It must reproduce a regulated plasma-derived manufacturing process and satisfy comparability and quality requirements.
The weakness is that process patents generally provide narrower protection than composition patents. A competitor could seek a different purification, viral-clearance, or formulation route. Octapharma’s stronger barriers are likely to be:
- Access to human plasma.
- Manufacturing capacity.
- Regulatory history.
- Quality systems.
- Hospital contracts.
- Specialist familiarity.
- Supply reliability during bleeding emergencies.
When does FIBRYGA lose exclusivity?
FIBRYGA does not have a clearly identified small-molecule patent cliff. The relevant loss-of-exclusivity event would be the approval and commercial launch of a competing fibrinogen concentrate, not the expiration of one Orange Book-listed patent.
The likely timing of competitive erosion depends on:
| Factor |
Effect on FIBRYGA |
| Biologic regulatory pathway |
Slows conventional generic substitution |
| Plasma-derived manufacturing |
Raises development and scale requirements |
| Rare-disease population |
Limits commercial return for entrants |
| Cryoprecipitate availability |
Caps pricing power |
| Hospital contracts |
Can protect incumbent volume |
| Supply disruptions |
Can accelerate competitor adoption |
| Process patent expiry |
May reduce legal barriers but not manufacturing barriers |
No public event establishes a definitive FIBRYGA market-wide exclusivity expiration date. The practical exclusivity period is therefore governed by regulatory, manufacturing, and commercial barriers.
Which companies are challenging FIBRYGA?
No major public Paragraph IV challenge is associated with FIBRYGA because the product is a biologic rather than an Orange Book-listed small molecule. Publicly visible competition is more likely to emerge through independently developed fibrinogen concentrates, regional plasma products, or expanded use of cryoprecipitate.
Principal competitors
- CSL Behring, through RiaSTAP and related plasma-derived products.
- LFB, through fibrinogen products in selected markets.
- Takeda, through plasma-derived products and blood-protein infrastructure.
- National blood services, which supply cryoprecipitate.
- Regional plasma fractionators and specialty biologics companies.
Competition is often country-specific. A product with strong U.S. positioning may have a different share profile in Europe, Latin America, or Asia because reimbursement, blood-product policy, and local manufacturing vary.
What litigation and settlement risks affect FIBRYGA?
No major publicly established FIBRYGA patent litigation or settlement agreement defines the product’s current market position. The litigation risk is more likely to arise from:
- Patent disputes over fibrinogen purification or formulation.
- Manufacturing process claims.
- Regulatory exclusivity disputes.
- Product-liability claims involving bleeding outcomes.
- Plasma sourcing and supply agreements.
- Contract disputes with hospitals or distributors.
The absence of a prominent patent dispute reduces near-term legal volatility. It does not eliminate manufacturing or regulatory risk.
What is FIBRYGA’s financial trajectory?
Octapharma does not publicly report FIBRYGA revenue as a standalone product line. The company is privately held, and available corporate disclosures generally do not provide the product-level sales, gross margin, regional revenue, or operating-profit data required to construct a verified FIBRYGA financial series.
Financial trajectory indicators
| Metric |
Public visibility |
Commercial interpretation |
| Product revenue |
Not separately disclosed |
Prevents precise CAGR or valuation modeling |
| Unit volume |
Not separately disclosed |
Demand must be inferred from market access |
| Pricing |
Country and contract dependent |
Hospital procurement determines net price |
| Gross margin |
Not disclosed |
Likely affected by plasma and fractionation costs |
| Market share |
Not consistently disclosed |
Competitive position varies by geography |
| R&D spending |
Not allocated to FIBRYGA |
Limits product-level return analysis |
| Manufacturing investment |
Corporate-level disclosure |
Supports supply reliability and portfolio growth |
The financial profile is likely characterized by relatively low patient volume, high value per treatment episode, and meaningful gross-margin sensitivity to plasma costs and manufacturing utilization. Revenue can grow through geographic expansion, new hospital protocols, and increased use in acquired bleeding, but the market remains bounded by rare disease prevalence and competing blood products.
Revenue exposure
FIBRYGA’s revenue exposure is concentrated in:
- Hematology treatment centers.
- Surgical hospitals.
- Trauma centers.
- Intensive-care units.
- Obstetric hemorrhage protocols where permitted.
- National reimbursement decisions.
- Plasma supply availability.
The product’s episodic use can create quarter-to-quarter volatility. Emergency demand may increase during supply shortages affecting competing fibrinogen products or cryoprecipitate, but those gains may not persist after supply normalizes.
What generic or biosimilar launch risks exist for FIBRYGA?
The probability of a rapid generic-style launch is low. A competing biologic would face a longer development cycle, higher capital requirements, and less predictable commercial returns than a standard oral drug.
The primary launch risks are:
- Regulatory uncertainty around comparability and clinical requirements.
- Limited access to suitable plasma.
- High cost of fractionation and viral clearance.
- Small addressable patient population.
- Entrenched hospital protocols.
- Need for emergency-grade supply reliability.
- Competitive pricing from cryoprecipitate.
- Difficulty securing reimbursement at a premium price.
The most credible competitive threat is not an immediate biosimilar substitution event. It is gradual share pressure from another fibrinogen concentrate with broader acquired-bleeding labeling, superior supply reliability, lower price, or stronger hospital contracting.
How does FIBRYGA compare with other Octapharma products?
Octapharma’s portfolio includes immunoglobulins, coagulation factors, and other plasma-derived therapies. FIBRYGA fits the company’s specialty hematology strategy but occupies a narrower market than immunoglobulin products.
| Product characteristic |
FIBRYGA |
Broad immunoglobulin portfolio |
| Patient population |
Rare bleeding disorders and acute bleeding settings |
Larger autoimmune, immunodeficiency, and neurologic populations |
| Demand pattern |
Episodic and hospital-based |
Chronic and recurrent |
| Main supply constraint |
Fibrinogen-specific plasma fractionation |
Plasma supply and immunoglobulin capacity |
| Pricing sensitivity |
Hospital procurement and reimbursement |
Specialty pharmacy and hospital reimbursement |
| Growth potential |
Protocol expansion and geographic access |
Larger population and broader indications |
FIBRYGA may have strategic value beyond its direct revenue because it strengthens Octapharma’s position with hematologists, surgical centers, and blood-management programs.
What is the geographic market outlook for FIBRYGA?
The United States is commercially important because of its large hospital market and established use of fibrinogen concentrates in selected settings. Europe offers a fragmented but strategically important market, with national reimbursement and blood-product policies influencing adoption.
Growth opportunities are strongest where:
- Cryoprecipitate supply is limited.
- Hospital systems adopt goal-directed coagulation management.
- Fibrinogen testing is routine.
- National guidelines support concentrate use.
- Octapharma has an established distribution network.
- Reimbursement recognizes the value of rapid, standardized replacement.
Emerging markets may offer volume growth but face lower pricing, local plasma-product preferences, and regulatory barriers.
What manufacturing and intellectual-property barriers protect FIBRYGA?
The most important barriers are operational:
- Human plasma collection.
- Donor screening.
- Fractionation capacity.
- Viral inactivation and removal.
- Batch consistency.
- Cold-chain and inventory management.
- Regulatory inspection readiness.
- Emergency supply commitments.
These barriers are difficult for a new entrant to overcome quickly. Plasma-derived biologics also face a different risk profile from recombinant products because raw-material supply and batch variability can affect production planning.
A competitor that develops a recombinant fibrinogen product could reduce dependence on human plasma, but it would face substantial clinical, regulatory, manufacturing, and cost hurdles. Such a product would represent a longer-term technological threat rather than an immediate FIBRYGA substitute.
Key Takeaways
- FIBRYGA is a specialized human fibrinogen concentrate marketed by Octapharma.
- Its U.S. FDA approval covers congenital fibrinogen deficiency in adults and adolescents, including acute bleeding and perioperative management.
- The product competes with RiaSTAP, other fibrinogen concentrates, and cryoprecipitate.
- FIBRYGA is regulated as a biologic and is principally relevant to the FDA Purple Book, not the Orange Book.
- No public Paragraph IV challenge or definitive FIBRYGA patent cliff establishes a near-term generic launch event.
- Commercial protection rests heavily on plasma supply, manufacturing know-how, regulatory history, and hospital relationships.
- Octapharma does not publicly disclose standalone FIBRYGA revenue, preventing a verified product-level financial CAGR or margin analysis.
- Financial growth is most likely to come from geographic expansion, hospital protocol adoption, acquired-bleeding use, and supply advantages.
- The most credible competitive threat is another fibrinogen concentrate with broader labeling, lower price, or stronger supply reliability.
- Cryoprecipitate remains a meaningful price and availability constraint on FIBRYGA’s market expansion.
Frequently Asked Questions
Is FIBRYGA a biosimilar?
No. FIBRYGA is an independently manufactured plasma-derived fibrinogen biologic. It is not marketed as a biosimilar to RiaSTAP.
Does FIBRYGA have an Orange Book patent?
FIBRYGA is a biologic, so its principal FDA reference framework is the Purple Book rather than the Orange Book. Conventional Orange Book Paragraph IV litigation is not the expected competitive pathway.
Who manufactures FIBRYGA?
Octapharma manufactures and commercializes FIBRYGA through its global plasma-derived medicines business. Octapharma USA markets the product in the United States. [1]
Is FIBRYGA used for trauma bleeding?
Use in trauma and acquired bleeding depends on country-specific labeling, institutional protocols, and clinical guidelines. The U.S. approval is centered on congenital fibrinogen deficiency and perioperative management in the labeled population. [1]
Why is FIBRYGA’s revenue not publicly available?
Octapharma is privately held and does not generally report standalone product revenue for FIBRYGA. Public disclosures therefore support market and regulatory analysis but not a verified product-level income statement.
References
- U.S. Food and Drug Administration. (2017). FIBRYGA prescribing information. https://www.fda.gov
- Octapharma. (n.d.). FIBRYGA: Human fibrinogen concentrate. https://www.octapharma.com
- European Medicines Agency. (n.d.). Fibrinogen human product information. https://www.ema.europa.eu
- National Organization for Rare Disorders. (n.d.). Congenital afibrinogenemia. https://rarediseases.org
- U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
